---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-002915"
form_type: "8-K"
ticker: "ERNA"
cik: "0000748592"
company_name: "Ernexa Therapeutics Inc."
filed_at: "2024-01-19T23:59:59+00:00"
generated_at: "2026-06-06T21:36:46.305669+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Eterna receives Nasdaq non-compliance notice over board independence; has 45 days to submit plan

## Summary
- Received Nasdaq notice on Jan 17, 2024 for failing majority independent board and audit committee rules under Listing Rule 5605.
- Triggered by appointment of Dorothy Clarke as GC and her resignation from board committees, plus Sanjeev Luther joining board.
- Company has 45 days to submit a compliance plan; Nasdaq may grant up to 180-day extension.
- No immediate effect on listing; common stock continues trading under symbol ERNA.
- Company is evaluating director candidates to regain compliance.

## SEC filing metadata
- accession: 0001140361-24-002915
- form_type: 8-K
- ticker: ERNA
- cik: 0000748592
- company_name: Ernexa Therapeutics Inc.
- filed_at: 2024-01-19T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/748592/000114036124002915/0001140361-24-002915-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/748592/000114036124002915/ef20019104_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-002915
- JSON: https://secwatch.observer/filing/0001140361-24-002915.json
- Plain text: https://secwatch.observer/filing/0001140361-24-002915.txt

## Key facts
- Listing & Compliance Notices
  Ernexa Therapeutics Inc. received a nasdaq deficiency notice notice regarding board independence (rules 5605).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: board independence
  - Rules: 5605
  source text: January 17, 2024, Eterna Therapeutics Inc. (the “Company”) received a notice (the “Notice”) from the Listing Qualifications Staff (“Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) stating that, due to the appointment of Dorothy Clarke as the Company’s General Counsel, Ms. Clarke’s subsequent resignation from the committees of the Company’s Board of Directors (the “Board”) and the appointment of Sanjeev Luther as a member of the Board, the Company no longer complies with Nasdaq’s majority independent board and independent audit committee requirements as set forth in Nasdaq Listing Rule 5605
  evidence_url: https://www.sec.gov/Archives/edgar/data/748592/000114036124002915/0001140361-24-002915-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.